Trials / Not Yet Recruiting
Not Yet RecruitingNCT06656234
The Effectiveness and Safety of Glofitamab in Real-World Clinical Practice Among Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Prospective, Observational, Multicenter Study
- Status
- Not Yet Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (estimated)
- Sponsor
- Ruijin Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the the efficacy and safety in the real-world settings of glofitamab among Chinese R/R DLBCL participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Glofitamab | Glofitamab will be administered at the discretion of the physician per local clinical practice and local labeling. |
| DRUG | Obinutuzumab | Obinutuzumab pre-treatment is given intravenously at a dose of 1g on Cycle 1 Day 1. |
Timeline
- Start date
- 2024-10-30
- Primary completion
- 2027-09-15
- Completion
- 2028-09-15
- First posted
- 2024-10-24
- Last updated
- 2024-10-24
Locations
1 site across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06656234. Inclusion in this directory is not an endorsement.